A Phase II trial of Elacestrant (RAD1901) in patient with advanced breast cancer

Trial Profile

A Phase II trial of Elacestrant (RAD1901) in patient with advanced breast cancer

Planning
Phase of Trial: Phase II

Latest Information Update: 01 Mar 2018

At a glance

  • Drugs Elacestrant (Primary)
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Radius Health Inc.
  • Most Recent Events

    • 01 Mar 2018 According to a Radius Health media release, company received the scientific advice from the EMA and FDA for this study. Also, based on results of the study, this trial would support applications for global marketing approvals for elacestrant as a third-line monotherapy.
    • 01 Mar 2018 Planned number of patients changed from 200 to 300, according to a Radius Health media release.
    • 01 Mar 2018 According to a Radius Health media release, this study is expected to initiate in the second half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top